Adc Therapeutics Sa Adc Therapeutics Doses First Patient In Pivotal Clinical | Latest News RSS feed

Adc Therapeutics Sa Adc Therapeutics Doses First Patient In Pivotal Clinical - Latest News


ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The trial will enroll approximately 140 patients with relapsed or refractory DLBCL at multiple centers in the USA and Europe. “We are pleased to have dosed the first patient in our registrational Phas... read more

ADC Therapeutics SA - ADC Therapeutics Doses First Patient in Pivotal Clinical ...

Phase II trial evaluating efficacy and safety of CD19-targeting antibody drug conjugate intended to support submission of Biologics License Application Top-line data expected in third quarter of 2019 ... read more

ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-402 in CD-19 Positive B-cell Non-Hodgkin Lymphomas

The first stage is a dose escalation phase which will recruit up to 30 patients ... clinical trials, with a deep pipeline of other ADCs in preclinical development. More information regarding these tri... read more

Looking for another news?


ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-402 for Patients with B-cell lineage Acute Lymphoblastic Leukemia

The first stage (Phase Ia) is a dose escalation ... Ia/Ib clinical trials in patients with relapsed or refractory B-cell lineage non-Hodgkin lymphoma and relapsed or refractory B-cell lineage acute ly... read more


ADC Therapeutics : Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The trial will enroll approximately 140 patients with relapsed or refractory DLBCL at multiple centers in the USA and Europe. "We are pleased to have dosed the first patient in our registrational Phas... read more

ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma

The overall response rate with doses ... clinical trials in patients with relapsed or refractory B-cell lineage non-Hodgkin lymphoma and relapsed or refractory B-cell lineage acute lymphoblastic leuke... read more

ADC Therapeutics Receives FDA Clearance to Begin Clinical Studies for Its Second Novel Antibody Drug Conjugate ADCT-402 against Lymphomas and Leukemia

LAUSANNE, Switzerland & LONDON & MURRAY HILL, N.J.--(BUSINESS WIRE)--ADC Therapeutics SA (ADCT ... single doses, and it outperformed other CD19 targeted ADCs currently in clinical development. The fir... read more

ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma

First Clinical Data of ADCT-402 Demonstrate Encouraging Antitumor Activity in Relapsed or Refractory Non-Hodgkin's Lymphoma LAUSANNE, SWITZERLAND / ACCESSWIRE / June 16, 2017 / ADC Therapeutics ... wi... read more

ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced ... read more

ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma

ADC Therapeutics Presents First ... 57% in patients with relapsing or refractory diffuse large B-cell lymphoma (DLBCL). The maximum tolerated dose has not yet been reached. Dr. Jay Feingold, Chief Med... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us